- Conditions
- Breast Neoplasm
- Interventions
- Yoga
- Behavioral
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 7,072
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Paclitaxel, Carboplatin, Sunitinib
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 14
- States / cities
- Fort Lauderdale, Florida • Fort Myers, Florida • Gainesville, Georgia + 9 more
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), Sarcoma
- Interventions
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Drug
- Lead sponsor
- Radiopharm Theranostics, Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska + 1 more
- Conditions
- Advanced Glioblastoma, Advanced Colorectal Cancer, Advanced Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
- Interventions
- ONC201
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Cirtuvivint, Olaparib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Aurora, Colorado
- Conditions
- Sensation Disorders, Sensation, Phantom, Pain, Postoperative, Pain, Chronic, Numbness, Sensory Disorder, Sensory Defect, Phantom Pain, Phantom Sensation
- Interventions
- Sensory testing
- Diagnostic Test
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2033
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Interventions
- Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 728
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more
- Conditions
- Female Breast Cancer
- Interventions
- docetaxel + cyclophosphamide + pegfilgrastim
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
- Interventions
- BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 11
- States / cities
- Clovis, California • Los Angeles, California • Newport Beach, California + 6 more
- Conditions
- Cachexia
- Interventions
- GTx-024, Placebo
- Drug
- Lead sponsor
- GTx
- Industry
- Eligibility
- Not listed
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 50
- States / cities
- Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 41 more
- Conditions
- Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Glioma, Ovarian Neoplasms, Stomach Neoplasms
- Interventions
- Not listed
- Lead sponsor
- Harvard Medical School (HMS and HSDM)
- Other
- Eligibility
- Not listed
- Enrollment
- 30,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Visica 2™ Treatment System, Cryoablation, Surgical Resection
- Device · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Percutaneous Removal and Margin Ablation
- Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Breast Carcinoma
- Interventions
- Aerobic Exercise, Bioelectric Impedance Analysis, Consultation, Educational Intervention, Electronic Health Record Review, Nutritional Intervention, Physical Performance Testing, Psychosocial Care, Questionnaire Administration, Referral, Resistance Training, Spiritual Therapy, Tailored Intervention
- Other · Procedure · Behavioral
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California
- Conditions
- Breast Cancer
- Interventions
- Molecular Breast Imaging
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cancer, Pain Management, Opioid Use
- Interventions
- Intervention Participants
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Breast Cancer, Breast Carcinoma
- Interventions
- LEE-011, Fulvestrant, Placebo
- Drug
- Lead sponsor
- Melissa K Accordino
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 7 more
- Conditions
- Breast Cancer
- Interventions
- Mammography
- Radiation
- Lead sponsor
- Lunit Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Lovaza 4gm oral, Raloxifene 60 Mg Oral Tablet, Raloxifene 30 Mg Oral Tablet, Lovaza 4gm & Raloxifene 30mg
- Dietary Supplement · Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 35 Years to 70 Years · Female only
- Enrollment
- 266 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- clodronate disodium, demeclocycline hydrochloride, ibandronate sodium, tetracycline hydrochloride, zoledronic acid, laboratory biomarker analysis, adjuvant therapy, computed tomography, dual x-ray absorptiometry
- Drug · Other · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer
- Interventions
- Reimbursement
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Durvalumab, Olaparib
- Biological · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Breast Cancer
- Interventions
- E7389
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 48 more
- Conditions
- Advanced Estrogen Receptor Positive HER2- Breast Cancer
- Interventions
- GS-5829, Exemestane, Fulvestrant
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Stanford, California • Boston, Massachusetts • Minneapolis, Minnesota + 3 more